"The groundwork of all happiness is health." - Leigh Hunt

Federal government now not covers COVID medications

Oct. 30, 2023 – Two medications that help prevent severe COVID-19 illness will now not be distributed by the federal government starting Wednesday.

The transition to industrial distribution of the medication Paxlovid And Lagevrio is one other step toward privatizing pandemic measures previously implemented by the federal government under the federal public health emergency that led to May.

The transition is being closely watched after the discharge of the seasonal COVID vaccine in September was marred by distribution delays and insurance processing errors. Those problems were attributed to the incontrovertible fact that it was the primary time the shots were distributed without federal government involvement.

People with certain risk aspects, resembling other medical conditions or older age, who take the antiviral medications soon after COVID symptoms appear are less prone to develop severe COVID illness or die from the disease.

According to Reuters, the manufacturer of Paxlovid wants to extend the worth of the drug from $530 to $1,390 reported. However, most individuals will proceed to have the ability to get the drug totally free through the top of 2024 and totally free or at low price through 2028, based on the U.S. Department of Health and Human Services announced this month.

The weekly variety of COVID-related deaths has risen steadily since reaching an all-time low of 484 in the primary week of July. The latest weekly COVID death count was 1,339 people for the week ending September 30. (Death data reported by the CDC is several weeks behind testing and hospitalization data.) All other COVID metrics are trending downward, with nearly 9% of tests showing positive cases for the week ending Oct. 21 and hospitalizations declining by a fraction of a percentage point, settling in During the 12 months the week ending October twenty first totaled 16,186.

Correction: An earlier version of this story incorrectly stated that problems distributing COVID-19 drugs were because they were being distributed by the federal government for the primary time. In fact, that is the primary time these drugs will probably be distributed without government support.